SDM laser effective for CSC

Article

According to recently published data, an 810 nm subthreshold diode micropulse (SDM) laser is effective in the treatment of chronic central serous chorioretinopathy (CSC).

According to recently published data, an 810 nm subthreshold diode micropulse (SDM) laser is effective in the treatment of chronic central serous chorioretinopathy (CSC).

The study, performed by Dr Luiz Roisman et al. (Federal University of Sao Paulo, Brazil), included 15 patients in total who were randomized into two groups to either receive SDM laser treatment or a sham procedure.

Ten patients received SDM laser treatment along the detached area, the remaining five patients received sham treatment. At 3 months follow up, the best-corrected visual acuity (BCVA) was found to be significantly improved in the laser treatment group. All patients allocated to the sham group required treatment after 3 months. Central macular thickness was noted to be better in both groups.

It was concluded that SDM laser treatment was effective in the treatment of chronic CSC without causing any damage to the retina.

For more detailed information please view the abstract in Ophthalmic Surgery, Lasers and Imaging.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.